Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Top Cited Papers
Open Access
- 1 August 2015
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 5 (8), 842-849
- https://doi.org/10.1158/2159-8290.cd-14-1467
Abstract
Mutations in the MET exon 14 RNA splice acceptor and donor sites, which lead to exon skipping, deletion of the juxtamembrane domain containing the CBL E3-ubiquitin ligase-binding site, and decreased turnover of the resultant aberrant MET protein, were previously reported to be oncogenic in preclinical models. We now report responses to the MET inhibitors crizotinib and cabozantinib in four patients with stage IV lung adenocarcinomas harboring mutations leading to MET exon 14 skipping, highlighting a new therapeutic strategy for the 4% of lung adenocarcinoma patients whose tumors harbor this previously underappreciated genetic alteration. Significance: Oncogenic mutations in the MET exon 14 splice sites that cause exon 14 skipping occur in 4% of lung adenocarcinomas. We report responses to the MET inhibitors crizotinib and cabozantinib in patients with lung adenocarcinomas harboring MET exon 14 splice site mutations, identifying a new potential therapeutic target in this disease. Cancer Discov; 5(8); 842–9. ©2015 AACR. See related commentary by Ma, p. 802. See related article by Frampton et al., p. 850. This article is highlighted in the In This Issue feature, p. 783Keywords
Other Versions
This publication has 25 references indexed in Scilit:
- MET As a Possible Target for Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- The transcriptional landscape and mutational profile of lung adenocarcinomaGenome Research, 2012
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthMolecular Cancer Therapeutics, 2011
- Ethnic Differences and Functional Analysis of MET Mutations in Lung CancerClinical Cancer Research, 2009
- Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung CancersJournal of Thoracic Oncology, 2009
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Direct multiplexed measurement of gene expression with color-coded probe pairsNature Biotechnology, 2008
- An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic MechanismsCancer Research, 2007
- Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung CancerCancer Research, 2005